{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:49:31Z","timestamp":1762102171291,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K10150"],"award-info":[{"award-number":["JP16K10150"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10147-018-1246-y","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T07:17:07Z","timestamp":1519283827000},"page":"1508-1514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan"],"prefix":"10.1007","volume":"24","author":[{"given":"Hisashi","family":"Uhara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"issue":"4","key":"1246_CR1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/CMR.0000000000000359","volume":"27","author":"J Mangana","year":"2017","unstructured":"Mangana J, Cheng PF, Kaufmann C et al (2017) Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res 27(4):358\u2013368","journal-title":"Melanoma Res"},{"key":"1246_CR2","unstructured":"CANCER STATISTICS IN JAPAN '16. Cancer information service NCC, Japan. https:\/\/ganjoho.jp\/en\/professional\/statistics\/brochure\/2016_en.html"},{"issue":"2","key":"1246_CR3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.17554\/j.issn.1819-6187.2016.04.84","volume":"4","author":"M Nishi","year":"2016","unstructured":"Nishi M (2016) Epidemiology of skin cancer in Japan. J Tumor 4(2):369\u2013373","journal-title":"J Tumor"},{"issue":"2","key":"1246_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5227\/skincancer.29.189","volume":"29","author":"Y Fujisawa","year":"2014","unstructured":"Fujisawa Y, Fujimoto M (2014) Statistics for malignant melanoma in Japan: a nation wide survey from 2005 to 2013. Skin Cancer 29(2):189\u2013194","journal-title":"Skin Cancer"},{"issue":"20","key":"1246_CR5","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135\u20132147","journal-title":"N Engl J Med"},{"issue":"12","key":"1246_CR6","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18(12):3242\u20133249","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1246_CR7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1523-1747.1998.00376.x","volume":"111","author":"S Jiveskog","year":"1998","unstructured":"Jiveskog S, Ragnarsson-Olding B, Platz A et al (1998) N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Investig Dermatol 111(5):757\u2013761","journal-title":"J Investig Dermatol"},{"issue":"26","key":"1246_CR8","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340\u20134346","journal-title":"J Clin Oncol"},{"issue":"7","key":"1246_CR9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681\u20131696","journal-title":"Cell"},{"issue":"1","key":"1246_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","volume":"80","author":"K Sakaizawa","year":"2015","unstructured":"Sakaizawa K, Ashida A, Uchiyama A et al (2015) Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci 80(1):33\u201337","journal-title":"J Dermatol Sci"},{"issue":"3","key":"1246_CR11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10147-013-0573-2","volume":"19","author":"H Uhara","year":"2014","unstructured":"Uhara H, Ashida A, Koga H et al (2014) NRAS mutations in primary and metastatic melanomas of Japanese patients. Int J Clin Oncol 19(3):544\u2013548","journal-title":"Int J Clin Oncol"},{"issue":"18","key":"1246_CR12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694\u20131703","journal-title":"N Engl J Med"},{"issue":"9992","key":"1246_CR13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386(9992):444\u2013451","journal-title":"Lancet"},{"key":"1246_CR14","first-page":"JCO2017741025","volume":"2017","author":"GV Long","year":"2017","unstructured":"Long GV, Eroglu Z, Infante J et al (2017) Long-Term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 2017:JCO2017741025","journal-title":"J Clin Oncol"},{"issue":"1","key":"1246_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12094-017-1706-2","volume":"20","author":"H Uhara","year":"2018","unstructured":"Uhara H, Kiyohara Y, Tsuda A et al (2018) Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan. Clin Transl Oncol 20(1):169\u2013175","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"1246_CR16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"26","key":"1246_CR17","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"issue":"17","key":"1246_CR18","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889\u20131894","journal-title":"J Clin Oncol"},{"key":"1246_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T et al (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211","journal-title":"BMC Med"},{"issue":"1","key":"1246_CR20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","volume":"89","author":"Y Fujisawa","year":"2018","unstructured":"Fujisawa Y, Yoshino K, Otsuka A et al. (2018) Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. J Dermatol Sci 89(1):60\u201366","journal-title":"J Dermatol Sci"},{"issue":"26","key":"1246_CR21","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454","journal-title":"N Engl J Med"},{"issue":"10","key":"1246_CR22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020\u20131030","journal-title":"J Clin Oncol"},{"issue":"9948","key":"1246_CR23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948):1109\u20131117","journal-title":"Lancet"},{"issue":"1","key":"1246_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"26","key":"1246_CR25","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"issue":"10","key":"1246_CR26","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T et al (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28(10):2377\u20132385","journal-title":"Ann Oncol"},{"issue":"4","key":"1246_CR27","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M et al (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38(4):e55\u2013e57","journal-title":"Diabetes Care"},{"issue":"1","key":"1246_CR28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","volume":"46","author":"T Shirai","year":"2016","unstructured":"Shirai T, Sano T, Kamijo F et al (2016) Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46(1):86\u201388","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"1246_CR29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134","journal-title":"Neurology"},{"issue":"4","key":"1246_CR30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384","journal-title":"Lancet Oncol"},{"issue":"3","key":"1246_CR31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/annonc\/mdv580","volume":"27","author":"S Kanameishi","year":"2016","unstructured":"Kanameishi S, Otsuka A, Nonomura Y et al (2016) Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 27(3):546\u2013547","journal-title":"Ann Oncol"},{"issue":"14","key":"1246_CR32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356","journal-title":"N Engl J Med"},{"issue":"7653","key":"1246_CR33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545(7653):175\u2013180","journal-title":"Nature"},{"issue":"12","key":"1246_CR34","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, Grob JJ, Nathan P et al (2016) Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17(12):1743\u20131754","journal-title":"Lancet Oncol"},{"issue":"7","key":"1246_CR35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873","journal-title":"Lancet Oncol"},{"key":"1246_CR36","unstructured":"Long GV AV, Menzies AM et al (2017) Randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): anti-PD-1 brain collaboration (ABC). Presented at: 2017 World Congress of Melanoma; October 18\u201321, 2017; Brisbane, Australia 2017;SMR09-6"},{"issue":"3","key":"1246_CR37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","volume":"27","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Stallworth DG, Kim Y et al (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27(3):434\u2013441","journal-title":"Ann Oncol"},{"issue":"5","key":"1246_CR38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522\u2013530","journal-title":"Lancet Oncol"},{"issue":"19","key":"1246_CR39","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835","journal-title":"N Engl J Med"},{"issue":"19","key":"1246_CR40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377(19):1813\u20131823","journal-title":"N Engl J Med"},{"issue":"3","key":"1246_CR41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdermsci.2007.12.001","volume":"50","author":"D Watanabe","year":"2008","unstructured":"Watanabe D, Goshima F, Mori I et al (2008) Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 50(3):185\u2013196","journal-title":"J Dermatol Sci"},{"key":"1246_CR42","first-page":"JCO2017737379","volume":"2017","author":"J Chesney","year":"2017","unstructured":"Chesney J, Puzanov I, Collichio F et al (2017) Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol 2017:JCO2017737379","journal-title":"J Clin Oncol"},{"issue":"7","key":"1246_CR43","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D et al (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28(7):1631\u20131639","journal-title":"Ann Oncol"},{"issue":"5","key":"1246_CR44","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.2012.12","volume":"106","author":"K Sakaizawa","year":"2012","unstructured":"Sakaizawa K, Goto Y, Kiniwa Y et al (2012) Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106(5):939\u2013946","journal-title":"Br J Cancer"},{"issue":"5","key":"1246_CR45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10147-016-0976-y","volume":"21","author":"A Ashida","year":"2016","unstructured":"Ashida A, Sakaizawa K, Mikoshiba A et al (2016) Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol 21(5):981\u2013988","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"1246_CR46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","volume":"27","author":"G Manson","year":"2016","unstructured":"Manson G, Norwood J, Marabelle A et al (2016) Biomarkers associated with checkpoint inhibitors. Ann Oncol 27(7):1199\u20131206","journal-title":"Ann Oncol"},{"issue":"6257","key":"1246_CR47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207\u2013211","journal-title":"Science"},{"issue":"9","key":"1246_CR48","doi-asserted-by":"crossref","first-page":"e1204507","DOI":"10.1080\/2162402X.2016.1204507","volume":"5","author":"H Inoue","year":"2016","unstructured":"Inoue H, Park JH, Kiyotani K et al (2016) Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 5(9):e1204507","journal-title":"Oncoimmunology"},{"issue":"2","key":"1246_CR49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jdermsci.2017.07.007","volume":"88","author":"Y Fujisawa","year":"2017","unstructured":"Fujisawa Y, Yoshino K, Otsuka A et al (2017) Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci 88(2):225\u2013231","journal-title":"J Dermatol Sci"},{"issue":"47","key":"1246_CR50","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","volume":"7","author":"Y Nakamura","year":"2016","unstructured":"Nakamura Y, Kitano S, Takahashi A et al (2016) Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 7(47):77404\u201377415","journal-title":"Oncotarget"},{"issue":"84","key":"1246_CR51","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(84):886\u2013894","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-018-1246-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1246-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1246-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:17:24Z","timestamp":1659061044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-018-1246-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1246-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Funds and Grant for research: ONO PHARMACEUTICAL CO., LTD, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd. Novartis, MSD, TAIHO Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Kyowa Hakko Kirin Company, Limited, Mitsubishi Tanabe Pharma Corporation, Esai, AbbVie, Maruho, DAIICHI SANKYO COMPANY, LIMITED, Tsumura, Porafarma, Mochida, Nihonkayaku, Acterion, Torii, KAKEN PHARMACEUTICAL CO., LTD. Consultancy fee: ONO PHARMACEUTICAL CO., LTD, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd. Novartis, MSD, Kyowa Hakko Kirin Company, Limited: Fee for speaking. ONO PHARMACEUTICAL CO., LTD, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd. Novartis, MSD, TAIHO Pharmaceutical Co., Ltd. Porafarma, Mitsubishi Tanabe Pharma Corporation, Maruho.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}